General Information
Product name
Sildenafil Tablets USP
Manufacturer Name
Lupin Limited
Icons in SDS
Company Information
company name
Lupin Limited
Section 2
SECTION 2: Hazards identification
Fire and Explosion Expected to be non-combustible. Health Consistent with its known effects on the nitric oxide/cGMP pathway, sildenafil tablets was shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated. After patients have taken sildenafil tablets, it is unknown when nitrates, if necessary, can be safely administered. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point. Sildenafil tablets are contraindicated in patients with a known hypersensitivity to sildenafil, as contained in sildenafil tablets and REVATIO, or any component of the tablet. Hypersensitivity reactions have been reported, including rash and urticaria. Do not use sildenafil tablets in patients who are using a GC stimulator, such as riociguat. PDE5 inhibitors, including sildenafil tablets, may potentiate the hypotensive effects of GC stimulators.
Environmental hazards
No information is available about the potential of this product to produce
